Weight-loss drugs like Ozempic are booming in popularity, but experts warn they aren't silver bullets for obesity.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to set them up with Wegovy, Zepbound and other weight-loss drugs.

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price tags of over $1,000 a month.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s Semaglutide medications Wegovy

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker medical awards recognize a trio of scientists without whom Ozempic and other blockbuster weight-loss drugs might not exist.

In a society that has so many people who are overweight, it is understandable there’s such a craze for new drugs that are helping people to lose weight. Drugs like Ozempic and Wegovy were developed for people with diabetes but have proven to be great resources for losing weight.